[Form 4] Viking Therapeutics, Inc Insider Trading Activity

Q: What are the terms of MDCX public warrants?

Each warrant allows purchase of one common share at $4.64 and expires on 15 November 2029 .

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Medicus Pharma Ltd. has filed Prospectus Supplement No. 6 to update its May 29, 2025 prospectus covering 2,260,000 common shares that may be issued upon exercise of publicly traded warrants priced at $4.64 and expiring on 15 November 2029. The supplement attaches Amendment No. 1 to a Current Report, which in turn files the Share Exchange Agreement dated 29 June 2025 among Medicus, Antev Limited and Antev security-holders. By incorporating the Agreement as Exhibit 2.1, the company provides investors with the definitive terms of a proposed transaction that would give Medicus access to Antev’s lead program, Teverelix, and related market opportunities.

The company’s common shares (symbol MDCX) last traded at $3.22 on 2 July 2025, below the warrant exercise price, while the warrants (MDCXW) closed at $1.00. Medicus remains classified as an “emerging growth company,” enabling reduced disclosure obligations. Investors are reminded that the securities involve a high degree of risk; comprehensive risk factors are detailed beginning on page 10 of the base prospectus.

The filing contains extensive forward-looking statements regarding the potential benefits, timing and commercial prospects of the Antev transaction and Teverelix development. These statements are subject to the customary cautionary language and are qualified by reference to the company’s 2024 Annual Report and other SEC filings.

Key takeaways for investors: (1) Formal publication of the Share Exchange Agreement increases transparency around the Antev acquisition; (2) 2.26 million additional shares could be issued, creating future dilution but also providing up to $10.5 million in gross proceeds if all warrants are exercised; (3) Near-term exercise is unlikely while the share price remains below $4.64.

Medicus Pharma Ltd. ha presentato il Supplemento al Prospetto n. 6 per aggiornare il prospetto del 29 maggio 2025 relativo a 2.260.000 azioni ordinarie che possono essere emesse al momento dell'esercizio di warrant negoziati pubblicamente, con prezzo di esercizio di 4,64 $ e scadenza al 15 novembre 2029. Il supplemento include l'Emendamento n. 1 a un Rapporto Corrente, che a sua volta deposita il Contratto di Scambio Azionario datato 29 giugno 2025 tra Medicus, Antev Limited e i detentori di titoli Antev. Incorporando il Contratto come Allegato 2.1, la società fornisce agli investitori i termini definitivi di una transazione proposta che consentirebbe a Medicus di accedere al programma principale di Antev, Teverelix, e alle opportunità di mercato correlate.

Le azioni ordinarie della società (simbolo MDCX) sono state scambiate l'ultima volta a 3,22 $ il 2 luglio 2025, sotto il prezzo di esercizio dei warrant, mentre i warrant (MDCXW) hanno chiuso a 1,00 $. Medicus rimane classificata come "società in crescita emergente", beneficiando di obblighi di divulgazione ridotti. Si ricorda agli investitori che questi titoli comportano un alto grado di rischio; i fattori di rischio completi sono dettagliati a partire dalla pagina 10 del prospetto base.

Il deposito contiene numerose dichiarazioni previsionali riguardanti i potenziali benefici, i tempi e le prospettive commerciali della transazione con Antev e dello sviluppo di Teverelix. Tali dichiarazioni sono soggette al consueto linguaggio cautelativo e sono qualificate con riferimento al Rapporto Annuale 2024 della società e ad altri documenti SEC.

Punti chiave per gli investitori: (1) La pubblicazione formale del Contratto di Scambio Azionario aumenta la trasparenza sull'acquisizione di Antev; (2) potrebbero essere emesse 2,26 milioni di azioni aggiuntive, generando una futura diluizione ma fornendo fino a 10,5 milioni di $ di ricavi lordi se tutti i warrant venissero esercitati; (3) è improbabile un esercizio a breve termine finché il prezzo delle azioni rimane sotto i 4,64 $.

Medicus Pharma Ltd. ha presentado el Suplemento al Prospecto n. 6 para actualizar su prospecto del 29 de mayo de 2025 que cubre 2.260.000 acciones comunes que pueden emitirse al ejercer warrants negociados públicamente, con un precio de ejercicio de 4,64 $ y vencimiento el 15 de noviembre de 2029. El suplemento adjunta la Enmienda n. 1 a un Informe Actual, que a su vez presenta el Acuerdo de Intercambio de Acciones fechado el 29 de junio de 2025 entre Medicus, Antev Limited y los tenedores de valores de Antev. Al incorporar el Acuerdo como Anexo 2.1, la compañía proporciona a los inversores los términos definitivos de una transacción propuesta que otorgaría a Medicus acceso al programa principal de Antev, Teverelix, y a las oportunidades de mercado relacionadas.

Las acciones comunes de la compañía (símbolo MDCX) se negociaron por última vez a 3,22 $ el 2 de julio de 2025, por debajo del precio de ejercicio de los warrants, mientras que los warrants (MDCXW) cerraron a 1,00 $. Medicus sigue clasificada como una "empresa emergente en crecimiento", lo que permite obligaciones de divulgación reducidas. Se recuerda a los inversores que los valores implican un alto grado de riesgo; los factores de riesgo detallados se encuentran desde la página 10 del prospecto base.

La presentación contiene amplias declaraciones prospectivas sobre los posibles beneficios, el calendario y las perspectivas comerciales de la transacción con Antev y el desarrollo de Teverelix. Estas declaraciones están sujetas al lenguaje habitual de advertencia y se califican con referencia al Informe Anual 2024 de la compañía y otros documentos presentados ante la SEC.

Puntos clave para los inversores: (1) La publicación formal del Acuerdo de Intercambio de Acciones aumenta la transparencia sobre la adquisición de Antev; (2) podrían emitirse 2,26 millones de acciones adicionales, lo que generaría dilución futura pero también proporcionaría hasta 10,5 millones de $ en ingresos brutos si se ejercen todos los warrants; (3) es poco probable que se ejerzan pronto mientras el precio de la acción se mantenga por debajo de 4,64 $.

Medicus Pharma Ltd. a déposé le supplément n° 6 au prospectus daté du 29 mai 2025 afin de mettre à jour son prospectus couvrant 2 260 000 actions ordinaires pouvant être émises lors de l'exercice de bons de souscription négociés publiquement, au prix d'exercice de 4,64 $ et expirant le 15 novembre 2029. Le supplément joint l'amendement n° 1 à un rapport actuel, qui dépose à son tour l'accord d'échange d'actions daté du 29 juin 2025 entre Medicus, Antev Limited et les détenteurs de titres Antev. En incorporant l'accord en tant qu'annexe 2.1, la société fournit aux investisseurs les termes définitifs d'une transaction proposée qui donnerait à Medicus accès au programme principal d'Antev, Teverelix, ainsi qu'aux opportunités de marché associées.

Les actions ordinaires de la société (symbole MDCX) se sont négociées pour la dernière fois à 3,22 $ le 2 juillet 2025, en dessous du prix d'exercice des bons, tandis que les bons (MDCXW) ont clôturé à 1,00 $. Medicus reste classée comme une « entreprise en croissance émergente », ce qui permet des obligations de divulgation réduites. Les investisseurs sont rappelés que ces titres comportent un niveau de risque élevé ; les facteurs de risque détaillés commencent à la page 10 du prospectus de base.

Le dépôt contient de nombreuses déclarations prospectives concernant les avantages potentiels, le calendrier et les perspectives commerciales de la transaction avec Antev et du développement de Teverelix. Ces déclarations sont soumises aux mentions habituelles de prudence et sont qualifiées par référence au rapport annuel 2024 de la société et à d'autres dépôts auprès de la SEC.

Points clés pour les investisseurs : (1) La publication officielle de l'accord d'échange d'actions accroît la transparence autour de l'acquisition d'Antev ; (2) 2,26 millions d'actions supplémentaires pourraient être émises, entraînant une dilution future mais fournissant jusqu'à 10,5 millions de $ de produits bruts si tous les bons sont exercés ; (3) un exercice à court terme est peu probable tant que le cours de l'action reste inférieur à 4,64 $.

Medicus Pharma Ltd. hat den Nachtrag Nr. 6 zum Prospekt vom 29. Mai 2025 eingereicht, um 2.260.000 Stammaktien zu aktualisieren, die bei Ausübung öffentlich gehandelter Warrants mit einem Ausübungspreis von 4,64 $ und Ablaufdatum 15. November 2029 ausgegeben werden können. Der Nachtrag enthält die Änderung Nr. 1 zu einem aktuellen Bericht, der wiederum die Aktien-Tauschvereinbarung vom 29. Juni 2025 zwischen Medicus, Antev Limited und den Antev-Wertpapierinhabern einreicht. Durch die Einbindung der Vereinbarung als Anlage 2.1 stellt das Unternehmen den Investoren die endgültigen Bedingungen einer vorgeschlagenen Transaktion bereit, die Medicus Zugang zum Hauptprogramm von Antev, Teverelix, und den damit verbundenen Marktchancen verschaffen würde.

Die Stammaktien des Unternehmens (Symbol MDCX) wurden zuletzt am 2. Juli 2025 zu 3,22 $ gehandelt, unter dem Ausübungspreis der Warrants, während die Warrants (MDCXW) bei 1,00 $ schlossen. Medicus bleibt als "emerging growth company" eingestuft, was reduzierte Offenlegungspflichten ermöglicht. Investoren wird daran erinnert, dass diese Wertpapiere ein hohes Risiko bergen; umfassende Risikofaktoren sind ab Seite 10 des Basisprospekts detailliert aufgeführt.

Die Einreichung enthält umfangreiche zukunftsgerichtete Aussagen zu den potenziellen Vorteilen, dem Zeitplan und den kommerziellen Aussichten der Antev-Transaktion und der Teverelix-Entwicklung. Diese Aussagen unterliegen den üblichen Warnhinweisen und sind mit Verweis auf den Geschäftsbericht 2024 des Unternehmens und andere SEC-Einreichungen qualifiziert.

Wichtige Erkenntnisse für Investoren: (1) Die formelle Veröffentlichung der Aktien-Tauschvereinbarung erhöht die Transparenz bezüglich der Antev-Akquisition; (2) Es könnten 2,26 Millionen zusätzliche Aktien ausgegeben werden, was zu einer zukünftigen Verwässerung führt, aber auch bis zu 10,5 Millionen $ Bruttoerlösen bringen würde, falls alle Warrants ausgeübt werden; (3) Eine kurzfristige Ausübung ist unwahrscheinlich, solange der Aktienkurs unter 4,64 $ bleibt.

Positive

Formal filing of the Share Exchange Agreement with Antev Limited increases transparency and moves the proposed acquisition one step closer to completion.
Registration of warrant shares positions Medicus to raise up to $10.5 million in equity capital if market conditions allow warrant exercise.

Negative

Potential dilution: 2.26 million additional shares would expand the float by an estimated 7-8 % once exercised.
Warrant strike price ($4.64) exceeds current share price ($3.22), reducing the likelihood of near-term capital inflow and leaving funding needs unresolved.

Insights

TL;DR: Filing discloses definitive Antev share-exchange terms; neutral until completion and pricing converge.

The inclusion of the Share Exchange Agreement is procedurally important because it lets investors scrutinize deal mechanics, valuation, and closing conditions. However, the document does not confirm consummation, provide consideration metrics, or set a closing timetable, so material impact is deferred. From a capital-structure view, registration of 2.26 million warrant shares lifts potential dilution by roughly 7-8 % of outstanding equity, but the strike sits 44 % above the last trade, limiting immediate issuance. Overall, the supplement improves transparency yet does not, on its own, alter cash flows or strategic positioning until the Antev acquisition actually closes.

TL;DR: Disclosure advances Antev/Teverelix narrative; risk-reward unchanged pending clinical and regulatory milestones.

Teverelix is highlighted as the principal asset gained through Antev, but the filing offers no fresh clinical, regulatory, or commercial data. Investors therefore gain visibility into transaction structure rather than scientific derisking. The forward-looking statements reiterate potential market opportunities but underscore substantial uncertainties. Until Medicus publishes trial results, funding plans, or FDA guidance, the supplemental prospectus is informational rather than catalytic for valuation.

Punti chiave per gli investitori: (1) La pubblicazione formale del Contratto di Scambio Azionario aumenta la trasparenza sull'acquisizione di Antev; (2) potrebbero essere emesse 2,26 milioni di azioni aggiuntive, generando una futura diluizione ma fornendo fino a 10,5 milioni di $ di ricavi lordi se tutti i warrant venissero esercitati; (3) è improbabile un esercizio a breve termine finché il prezzo delle azioni rimane sotto i 4,64 $.

Puntos clave para los inversores: (1) La publicación formal del Acuerdo de Intercambio de Acciones aumenta la transparencia sobre la adquisición de Antev; (2) podrían emitirse 2,26 millones de acciones adicionales, lo que generaría dilución futura pero también proporcionaría hasta 10,5 millones de $ en ingresos brutos si se ejercen todos los warrants; (3) es poco probable que se ejerzan pronto mientras el precio de la acción se mantenga por debajo de 4,64 $.

Points clés pour les investisseurs : (1) La publication officielle de l'accord d'échange d'actions accroît la transparence autour de l'acquisition d'Antev ; (2) 2,26 millions d'actions supplémentaires pourraient être émises, entraînant une dilution future mais fournissant jusqu'à 10,5 millions de $ de produits bruts si tous les bons sont exercés ; (3) un exercice à court terme est peu probable tant que le cours de l'action reste inférieur à 4,64 $.

Wichtige Erkenntnisse für Investoren: (1) Die formelle Veröffentlichung der Aktien-Tauschvereinbarung erhöht die Transparenz bezüglich der Antev-Akquisition; (2) Es könnten 2,26 Millionen zusätzliche Aktien ausgegeben werden, was zu einer zukünftigen Verwässerung führt, aber auch bis zu 10,5 Millionen $ Bruttoerlösen bringen würde, falls alle Warrants ausgeübt werden; (3) Eine kurzfristige Ausübung ist unwahrscheinlich, solange der Aktienkurs unter 4,64 $ bleibt.

07/03/2025 - 03:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mancini Marianna

(Last)

(First)

(Middle)

C/O VIKING THERAPEUTICS, INC.

9920 PACIFIC HEIGHTS BLVD, SUITE 350

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, par value $0.00001 per share	07/02/2025		A		7,667⁽¹⁾	A	$0	381,801	D
Common Stock, par value $0.00001 per share	07/03/2025		S		4,266⁽²⁾	D	$27.7714⁽³⁾	377,535	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on July 2, 2025 upon the achievement of a non-financial performance goal.

2. These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.755 to $27.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.

	/s/ Michael Morneau, as Attorney-in-Fact	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What does Medicus Pharma’s Prospectus Supplement No. 6 cover?

It registers 2,260,000 common shares issuable upon exercise of public warrants and incorporates the Antev Share Exchange Agreement.

What are the terms of MDCX public warrants?

Each warrant allows purchase of one common share at $4.64 and expires on 15 November 2029.

Why is the Antev Share Exchange Agreement significant for MDCX investors?

It outlines the proposed acquisition of Antev Limited, potentially adding Teverelix to Medicus’s pipeline and expanding market opportunities.

Will the 2.26 million shares be issued immediately?

No. They are issuable only if holders exercise their warrants, which is unlikely while the share price remains below $4.64.

Is Medicus Pharma still considered an emerging growth company?

Yes. The filing confirms its status, which allows streamlined SEC disclosure requirements.

Where can investors find detailed risk factors for MDCX?

Risk factors start on page 10 of the base prospectus and are also included in the company’s 2024 Annual Report and other SEC filings.

[Form 4] Viking Therapeutics, Inc Insider Trading Activity

Insights

FAQ

What does Medicus Pharma’s Prospectus Supplement No. 6 cover?

What are the terms of MDCX public warrants?

Why is the Antev Share Exchange Agreement significant for MDCX investors?

Will the 2.26 million shares be issued immediately?

Is Medicus Pharma still considered an emerging growth company?

Where can investors find detailed risk factors for MDCX?

NASDAQ:VKTX

VKTX Rankings

VKTX Latest News

VKTX Latest SEC Filings

VKTX Stock Data

Trending News

[Form 4] Viking Therapeutics, Inc Insider Trading Activity

Insights

M&A Specialist neutral

Biopharma Industry Analyst neutral

FAQ

What does Medicus Pharma’s Prospectus Supplement No. 6 cover?

What are the terms of MDCX public warrants?

Why is the Antev Share Exchange Agreement significant for MDCX investors?

Will the 2.26 million shares be issued immediately?

Is Medicus Pharma still considered an emerging growth company?

Where can investors find detailed risk factors for MDCX?

NASDAQ:VKTX

VKTX Rankings

VKTX Latest News

VKTX Latest SEC Filings

VKTX Stock Data